Oscotec Inc (039200) - Total Liabilities

Latest as of September 2025: ₩31.19 Billion KRW ≈ $21.14 Million USD

Based on the latest financial reports, Oscotec Inc (039200) has total liabilities worth ₩31.19 Billion KRW (≈ $21.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 039200 cash flow conversion to assess how effectively this company generates cash.

Oscotec Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how Oscotec Inc's total liabilities have evolved over time, based on quarterly financial data. Check 039200 financial resilience to evaluate the company's liquid asset resilience ratio.

Oscotec Inc Competitors by Total Liabilities

The table below lists competitors of Oscotec Inc ranked by their total liabilities.

Company Country Total Liabilities
Hyundai Development Co
KO:294870
Korea ₩4.91 Trillion
Ningbo Thermal Power Co Ltd
SHG:600982
China CN¥11.13 Billion
Henan Hengxing Science & Technology Co Ltd
SHE:002132
China CN¥4.80 Billion
Fujian Nanping Sun Cable Co Ltd
SHE:002300
China CN¥4.44 Billion
Citic Press Corp
SHE:300788
China CN¥1.05 Billion
Gr. Sarantis S.A.
AT:SAR
Greece €232.08 Million
Gracell Biotechnologies Inc.
NASDAQ:GRCL
USA $268.86 Million
Preformed Line Products Company
NASDAQ:PLPC
USA $178.28 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Oscotec Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 039200 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oscotec Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oscotec Inc (2011–2024)

The table below shows the annual total liabilities of Oscotec Inc from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩38.42 Billion
≈ $26.04 Million
+1.47%
2023-12-31 ₩37.86 Billion
≈ $25.66 Million
+78.36%
2022-12-31 ₩21.23 Billion
≈ $14.39 Million
+5.40%
2021-12-31 ₩20.14 Billion
≈ $13.65 Million
-13.70%
2020-12-31 ₩23.34 Billion
≈ $15.82 Million
+10.58%
2019-12-31 ₩21.11 Billion
≈ $14.30 Million
-11.95%
2018-12-31 ₩23.97 Billion
≈ $16.24 Million
+24.17%
2017-12-31 ₩19.30 Billion
≈ $13.08 Million
+33.23%
2016-12-31 ₩14.49 Billion
≈ $9.82 Million
-35.84%
2015-12-31 ₩22.58 Billion
≈ $15.30 Million
+55.88%
2014-12-31 ₩14.49 Billion
≈ $9.82 Million
-6.44%
2013-12-31 ₩15.48 Billion
≈ $10.49 Million
-16.66%
2012-12-31 ₩18.58 Billion
≈ $12.59 Million
-16.50%
2011-12-31 ₩22.25 Billion
≈ $15.08 Million
--

About Oscotec Inc

KQ:039200 Korea Pharmaceuticals
Market Cap
$990.30 Million
₩1.46 Trillion KRW
Market Cap Rank
#9162 Global
#261 in Korea
Share Price
₩52000.00
Change (1 day)
-2.80%
52-Week Range
₩25450.00 - ₩62000.00
All Time High
₩66971.21
About

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more